

# Safety in mesenchymal stem cell transplantation

Matthie Robert\*

Center of Excellence in Stem Cell Research and Application, MA, USA; \*Corresponding author: matthierobert@gmail.com

**Received:** 15 January 2014 / **Accepted:** 19 February 2014 / **Published online:** 25 February 2014

© The Author(s) 2014. This article is published with open access by BioMedPress, Laboratory of Stem Cell Research and Application.

**Abstract**—To date, adult stem cell therapy has some achievements in the treatment of chronic disease. However, some risks in stem cell transplantation still serve as high barriers obstructing the pulling of these therapies into clinical use. Tumorigenicity is of almost concern after it is injected into patients. However, all clinical studies indexed in PubMed showed that there were no cases of tumor after transplantation. Especially in recent study published in *Cell Death and Disease*, Wang et al. (2013) showed that long-term cultured mesenchymal stem cells could develop the genomic mutations but cannot undergo malignant transformation. Moreover, the study also revealed these stem cells as capable of forming tumors. This commentary assesses the data generated to date, and discusses the conclusions drawn from various studies.

**Keywords**— Stem cells, Safety, Stem cell transplantation, Mesenchymal stem cell injection.

Mesenchymal stem cells are the most common stem cells used in study and in clinical observation. This population was firstly discovered by Friedenstein et al. (1974, 1976); they considered these stromal cells in bone marrow as colony-forming unit-fibroblast (CFU-f). Although the mesenchymal stem cells were firstly isolated from bone marrow (Gottipamula et al., 2014; Odabas et al., 2014), presently, they can be isolated from peripheral blood (Trivanovic et al., 2013), umbilical cord blood (Bieback et al., 2004; Sibov et al., 2012), banked umbilical cord blood (Phuc et al., 2012), umbilical cords (Martins et al., 2014; Santos et al., 2013), Wharton's jelly from the umbilical cord (Salehinejad et al., 2012), placenta (Salehinejad et al., 2012), decidua basalis (Huang et al., 2009), dental pulp (Gronthos et al., 2011), menstrual blood (Rossignoli et al., 2013), breast milk (Patki et al., 2010) and fat tissue (Ahrari et al., 2013; Ghorbani et al., 2014).

There are some different properties about MSCs among other sources. Dominici et al. (2006) suggested there are three criteria to confirm which cells are MSCs. Firstly, MSC must be plastic-adherent. Secondly, MSCs must express CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79alpha or CD19 and HLA-DR

surface molecules. Lastly, MSCs must successfully differentiate to osteoblasts, adipocytes and chondroblasts in vitro. MSCs were applied in the treatment of more than 10 diseases including Bronchopulmonary Dysplasia (Chang et al., 2014), drug-resistant tuberculosis (Skrahin et al., 2014), GVHD (Introna et al., 2013), stroke (Kim et al., 2013), autism (Lv et al., 2013), Crohn's disease (Forbes et al., 2014), hindlimb ischemia (Gupta et al., 2013), osteoarthritis (Bui et al., 2014; Orozco et al., 2013), multiple sclerosis (Bonab et al., 2012), perianal fistula (de la Portilla et al., 2013), heart failure (Mathiasen et al., 2012), craniofacial bone regeneration (Kaigler et al., 2013), liver cirrhosis (El-Ansary et al., 2012) and amyotrophic lateral sclerosis (Mazzini et al., 2012) among others. Fortunately, from more than 100 clinical studies related to mesenchymal stem cell transplantation from phase I to III, and in both autologous and allogeneous transplantation, there is no report about the adverse or the side-effect of mesenchymal stem cell transplantation.

The most frequently asked question, which serves as a subject of interest in all ethical committees about mesenchymal stem cells is the formation of tumors by MSCs. This is a hard barrier to enhance MSC transplantation as medical indication for disease treatment in hospital. In the present

times, almost all countries permit some clinical trials of non-cultured MSCs or minimal manipulations. In other countries, it is essential to control or certify the mutation status in the genomes of MSCs after long-term culture. In some studies, it is demonstrated that the stability in karyotypes of MSCs is an important condition for clinical observation.

Wang et al. (2013) showed that long-term mesenchymal stem cells could develop genomic mutations but do not undergo malignant transformations. In this study, authors used MSCs from umbilical cord as models. There were 9 cell clones of MSCs used to evaluate some properties related to genomic stability such as STR analysis, telomere length, karyotype, aCGH, gene expression and *in vivo* tumorigenesis. All clones were cultured from passage 1 (P1) to passage 30 (P30). Results showed that at P3, all clones exhibited normal phenotype, virtually all clones maintained normal karyotype at P3 and all clones senesced in culture, exhibiting decreased telomerase activity and shortened telomeres, after 30 passages. There were two clones that showed no DNA copy number variations (CNVs) at passage 30 (P30), seven clones that had  $\geq 1$  CNVs at P30 compared with P3, and one of these clones appeared as trisomic chromosome 10 at the late passage. Notably, no tumor was developed in immunodeficient mice injected with hUC-MSCs, regardless of whether the cells had CNVs at P30. mRNA-Seq analysis also showed that at late passage, MSCs decreased genomic stability; however, these genomic alterations did not undergo malignant transformation.

From these results, we recognized that after 30 passages, there was only a clone getting the trisomic chromosome 10, accounting for 11.11% (1/9 clones). However, almost all studies will stop the MSCs proliferation at P10. In fact, after 10 passages, there were enough MSCs for transplantation, especially autologous grafts. Besides, to reach 10 passages, MSCs have continuously expanded for at least 2 months. If MSCs were cultured to P10, few alternations would be carried out in their genomes and if there is any alternation, no tumor can be formed in grafted patients. In a previously published study, Wagner et al. (2008) showed that MSCs started to exhibit abnormal phenotypes from P7.

We suggest limiting the number of passages of MSCs if used in clinical observation. This limitation does not aim to reduce the tumor formation but *in vitro*, limited proliferation helps to decrease the senescence of MSCs. Aged MSCs significantly reduced the differentiation potential as well as proliferation (Tsai et al., 2011; Wagner et al., 2008). The first clinical trial to evaluate the safety was performed in 2003 in Italy (Mazzini et al., 2012). After 9 years, all the 19 patients with MSC transplantation derived from autologous bone marrow to treat amyotrophic lateral sclerosis showed no structural changes (including tumor formation) related to the baseline throughout the follow-up.

In conclusion, MSC transplantation is safe for humans. However, to improve transplantation efficacy, MSCs should

be cultured in limited time. It is better if MSCs are continuously cultured in passages lower than p7. In our commentary, we do not suggest the safety related to the xenogenic components used in culture medium as well as some transplantation related conditions and medical manipulations.

## Abbreviations

MSCs: Mesenchymal stem cells; CFU-f: Colony-forming unit-fibroblast; CNVs: copy number variations.

## Open Access

*This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.*

## References

- Ahrari, I., Purhabibi Zarandi, N., Khosravi Maharlooie, M., Monabati, A., Attari, A., and Ahrari, S. (2013). Adipose Tissue Derived Multipotent Mesenchymal Stromal Cells Can Be Isolated Using Serum-free Media. *Iranian Red Crescent medical journal* 15, 324-329.
- Bieback, K., Kern, S., Kluter, H., and Eichler, H. (2004). Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. *Stem cells (Dayton, Ohio)* 22, 625-634.
- Bonab, M.M., Sahraian, M.A., Aghsaie, A., Karvigh, S.A., Hosseinian, S.M., Nikbin, B., Lotfi, J., Khorramnia, S., Motamed, M.R., Togha, M., et al. (2012). Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study. *Current stem cell research & therapy* 7, 407-414.
- Bui, K.H.-T., Duong, T.D., Nguyen, N.T., Nguyen, T.D., Le, V.T., Mai, V.T., Phan, N.L.-C., Le, D.M., Phan, N.K., and Pham, P.V. (2014). Symptomatic knee osteoarthritis treatment using autologous adipose derived stem cells and platelet-rich plasma: a clinical study. *Biomedical Research and Therapy* 1, 2-8.
- Chang, Y.S., Ahn, S.Y., Yoo, H.S., Sung, S.I., Choi, S.J., Oh, W.I., and Park, W.S. (2014). Mesenchymal Stem Cells for Bronchopulmonary Dysplasia: Phase 1 Dose-Escalation Clinical Trial. *The Journal of pediatrics*.
- de la Portilla, F., Alba, F., Garcia-Olmo, D., Herrerias, J.M., Gonzalez, F.X., and Galindo, A. (2013). Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. *International journal of colorectal disease* 28, 313-323.
- El-Ansary, M., Abdel-Aziz, I., Mogawer, S., Abdel-Hamid, S., Hammam, O., Teaema, S., and Wahdan, M. (2012). Phase II trial: undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis. *Stem cell reviews* 8, 972-981.
- Forbes, G.M., Sturm, M.J., Leong, R.W., Sparrow, M.P., Segarajasingam,

- D., Cummins, A.G., Phillips, M., and Herrmann, R.P. (2014). A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association* 12, 64-71.
- Ghorbani, A., Jalali, S.A., and Varedi, M. (2014). Isolation of adipose tissue mesenchymal stem cells without tissue destruction: A non-enzymatic method. *Tissue & cell* 46, 54-58.
- Gottipamula, S., Ashwin, K.M., Muttigi, M.S., Kannan, S., Kolkundkar, U., and Seetharam, R.N. (2014). Isolation, expansion and characterization of bone marrow-derived mesenchymal stromal cells in serum-free conditions. *Cell and tissue research*.
- Gronthos, S., Arthur, A., Bartold, P.M., and Shi, S. (2011). A method to isolate and culture expand human dental pulp stem cells. *Methods in molecular biology (Clifton, NJ)* 698, 107-121.
- Gupta, P.K., Chullikana, A., Parakh, R., Desai, S., Das, A., Gottipamula, S., Krishnamurthy, S., Anthony, N., Pherwani, A., and Majumdar, A.S. (2013). A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia. *Journal of translational medicine* 11, 143.
- Huang, Y.C., Yang, Z.M., Chen, X.H., Tan, M.Y., Wang, J., Li, X.Q., Xie, H.Q., and Deng, L. (2009). Isolation of mesenchymal stem cells from human placental decidua basalis and resistance to hypoxia and serum deprivation. *Stem cell reviews* 5, 247-255.
- Introna, M., Lucchini, G., Dander, E., Galimberti, S., Rovelli, A., Balduzzi, A., Longoni, D., Pavan, F., Masciocchi, F., Algarotti, A., *et al.* (2013). Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*.
- Kaigler, D., Pagni, G., Park, C.H., Braun, T.M., Holman, L.A., Yi, E., Tarle, S.A., Bartel, R.L., and Giannobile, W.V. (2013). Stem cell therapy for craniofacial bone regeneration: a randomized, controlled feasibility trial. *Cell transplantation* 22, 767-777.
- Kim, S.J., Moon, G.J., Chang, W.H., Kim, Y.H., and Bang, O.Y. (2013). Intravenous transplantation of mesenchymal stem cells preconditioned with early phase stroke serum: current evidence and study protocol for a randomized trial. *Trials* 14, 317.
- Ly, Y.T., Zhang, Y., Liu, M., Qiuwaxi, J.N., Ashwood, P., Cho, S.C., Huan, Y., Ge, R.C., Chen, X.W., Wang, Z.J., *et al.* (2013). Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. *Journal of translational medicine* 11, 196.
- Martins, J.P., Santos, J.M., de Almeida, J.M., Filipe, M.A., de Almeida, M.V., Almeida, S.C., Agua-Doce, A., Varela, A., Gilljam, M., Stellan, B., *et al.* (2014). Towards an advanced therapy medicinal product based on mesenchymal stromal cells isolated from the umbilical cord tissue: quality and safety data. *Stem cell research & therapy* 5, 9.
- Mathiasen, A.B., Jorgensen, E., Qayyum, A.A., Haack-Sorensen, M., Eklund, A., and Kastrup, J. (2012). Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial). *American heart journal* 164, 285-291.
- Mazzini, L., Mareschi, K., Ferrero, I., Miglioretti, M., Stecco, A., Servo, S., Carriero, A., Monaco, F., and Fagioli, F. (2012). Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis: a long-term safety study. *Cytotherapy* 14, 56-60.
- Odabas, S., Elcin, A.E., and Elcin, Y.M. (2014). Isolation and characterization of mesenchymal stem cells. *Methods in molecular biology (Clifton, NJ)* 1109, 47-63.
- Orozco, L., Munar, A., Soler, R., Alberca, M., Soler, F., Huguet, M., Sentis, J., Sanchez, A., and Garcia-Sancho, J. (2013). Treatment of knee osteoarthritis with autologous mesenchymal stem cells: a pilot study. *Transplantation* 95, 1535-1541.
- Patki, S., Kadam, S., Chandra, V., and Bhonde, R. (2010). Human breast milk is a rich source of multipotent mesenchymal stem cells. *Human cell* 23, 35-40.
- Phuc, P.V., Ngoc, V.B., Lam, D.H., Tam, N.T., Viet, P.Q., and Ngoc, P.K. (2012). Isolation of three important types of stem cells from the same samples of banked umbilical cord blood. *Cell and tissue banking* 13, 341-351.
- Rosignoli, F., Caselli, A., Grisendi, G., Piccinno, S., Burns, J.S., Murgia, A., Veronesi, E., Loschi, P., Masini, C., Conte, P., *et al.* (2013). Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual blood. *BioMed research international* 2013, 901821.
- Salehinejad, P., Alitheen, N.B., Ali, A.M., Omar, A.R., Mohit, M., Janzamin, E., Samani, F.S., Torshizi, Z., and Nematollahi-Mahani, S.N. (2012). Comparison of different methods for the isolation of mesenchymal stem cells from human umbilical cord Wharton's jelly. *In vitro cellular & developmental biology Animal* 48, 75-83.
- Santos, J.M., Barcia, R.N., Simoes, S.I., Gaspar, M.M., Calado, S., Agua-Doce, A., Almeida, S.C., Almeida, J., Filipe, M., Teixeira, M., *et al.* (2013). The role of human umbilical cord tissue-derived mesenchymal stromal cells (UCX(R)) in the treatment of inflammatory arthritis. *Journal of translational medicine* 11, 18.
- Sibov, T.T., Severino, P., Marti, L.C., Pavon, L.F., Oliveira, D.M., Tobo, P.R., Campos, A.H., Paes, A.T., Amaro, E., Jr, L, F.G., *et al.* (2012). Mesenchymal stem cells from umbilical cord blood: parameters for isolation, characterization and adipogenic differentiation. *Cytotechnology* 64, 511-521.
- Skrahin, A., Ahmed, R.K., Ferrara, G., Rane, L., Poirer, T., Isaikina, Y., Skrahina, A., Zumla, A., and Maeurer, M.J. (2014). Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. *The lancet Respiratory medicine* 2, 108-122.

Trivanovic, D., Kocic, J., Mojsilovic, S., Krstic, A., Ilic, V., Djordjevic, I.O., Santibanez, J.F., Jovic, G., Terzic, M., and Bugarski, D. (2013). Mesenchymal stem cells isolated from peripheral blood and umbilical cord Wharton's jelly. *Srpski arhiv za celokupno lekarstvo* *141*, 178-186.

Tsai, C.C., Chen, Y.J., Yew, T.L., Chen, L.L., Wang, J.Y., Chiu, C.H., and Hung, S.C. (2011). Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST. *Blood* *117*, 459-469.

Wagner, W., Horn, P., Castoldi, M., Diehlmann, A., Bork, S., Saffrich, R., Benes, V., Blake, J., Pfister, S., Eckstein, V., *et al.* (2008). Replicative senescence of mesenchymal stem cells: a continuous and organized process. *PLoS one* *3*, e2213.

**Cite this article as:**

Robert, M. (2014). Safety of mesenchymal stem cell transplantation. *Biomedical Research And Therapy*, *1*(1), 21-24.